The impact of gastroesophageal reflux disease and its treatment on interstitial lung disease outcomes.

ABSTRACT:

Background

To determine the relationship between gastroesophageal reflux disease (GORD) and its treatment and interstitial lung disease in patients with systemic sclerosis (SSc).

Methods

SSc patients from the Australian Scleroderma Cohort Study (ASCS) were included. GORD was defined as self-reported GORD symptoms, therapy with a proton pump inhibitor (PPI) or histamine 2 receptor antagonist (H2RA) and/or the presence of reflux oesophagitis diagnosed endoscopically. The impact of GORD and its treatment on ILD features (including severity and time to ILD development) and survival was evaluated.

Results

GORD was a common manifestation affecting 1539/1632 (94%) of SSc patients. GORD affected 450/469 (96%) of those with SSc-ILD cohort. In SSc-ILD, there was no relationship

SUBMITTER: Quinlivan A 

PROVIDER: S-EPMC11197189 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature